{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:30:47Z","timestamp":1794814247691,"version":"4.9.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/pas.0000000000000324","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T13:28:28Z","timestamp":1410960508000},"page":"236-244","source":"Crossref","is-referenced-by-count":96,"title":["Leiomyosarcoma With Alternative Lengthening of Telomeres Is Associated With Aggressive Histologic Features, Loss of ATRX Expression, and Poor Clinical Outcome"],"prefix":"10.1097","volume":"39","author":[{"given":"Jau-Yu","family":"Liau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Huei","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ming","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Chieh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Han","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1097-0142(19920701)70:1<114::AID-CNCR2820700119>3.0.CO;2-U","article-title":". Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content.","volume":"70","author":"Gustafson","year":"1992","journal-title":"Cancer"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2001.19.12.3045","article-title":". Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.","volume":"19","author":"Fletcher","year":"2001","journal-title":"J Clin Oncol"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.ejso.2004.07.018","article-title":". Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.","volume":"30","author":"Massi","year":"2004","journal-title":"Eur J Surg Oncol"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/cncr.11617","article-title":". Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases.","volume":"98","author":"Deyrup","year":"2003","journal-title":"Cancer"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/gcc.20224","article-title":". The interactive online SKYM-FISH CGH database and the Entrez cancer chromosomes search database: linkage of chromosomal aberrations with the genome sequence.","volume":"44","author":"Knutsen","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/gcc.1118","article-title":". Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis.","volume":"31","author":"Wang","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":". Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.","volume":"20","author":"Hensley","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":". Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"IInd, Metzinger DS, DiMarco CS, et al.. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R10-11-20210131","first-page":"629","article-title":"IInd, Eisenhauer E, et al..","volume":"131","author":"Ricci","year":"2013","journal-title":"Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma Gynecol Oncol"},{"key":"R11-11-20210131","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cell.2013.01.010","article-title":"The role of telomeres in stem cells and cancer.","volume":"152","author":"Gunes","year":"2013","journal-title":"Cell"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":". TERT promoter mutations in familial and sporadic melanoma.","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":". Highly recurrent TERT promoter mutations in human melanoma.","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"R14-11-20210131","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000167814","article-title":". Telomere length maintenancean ALTernative mechanism.","volume":"122","author":"Royle","year":"2008","journal-title":"Cytogenet Genome Res"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrg2763","article-title":"Alternative lengthening of telomeres: models, mechanisms and implications.","volume":"11","author":"Cesare","year":"2010","journal-title":"Nat Rev Genet"},{"key":"R16-11-20210131","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1016\/j.febslet.2010.06.009","article-title":"Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.","volume":"584","author":"Henson","year":"2010","journal-title":"FEBS Lett"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2011.06.018","article-title":". Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.","volume":"179","author":"Heaphy","year":"2011","journal-title":"Am J Pathol"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.217.11.1","article-title":". A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.","volume":"11","author":"Henson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/NEN.0b013e3181e576cf","article-title":". Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.","volume":"69","author":"McDonald","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(03)12681-5","article-title":". Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.","volume":"361","author":"Hakin-Smith","year":"2003","journal-title":"Lancet"},{"key":"R21-11-20210131","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1750-3639.2012.00630.x","article-title":". Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.","volume":"23","author":"Nguyen","year":"2013","journal-title":"Brain Pathol"},{"key":"R22-11-20210131","first-page":"1759","article-title":". Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.","volume":"63","author":"Ulaner","year":"2003","journal-title":"Cancer Res"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1471-2407-10-254","article-title":". Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis.","volume":"10","author":"Venturini","year":"2010","journal-title":"BMC Cancer"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1158\/0008-5472.CAN-06-0273","article-title":". Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.","volume":"66","author":"Costa","year":"2006","journal-title":"Cancer Res"},{"key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":". DAXXATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"R26-11-20210131","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":". Altered telomeres in tumors with ATRX and DAXX mutations.","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"key":"R27-11-20210131","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/modpathol.2013.90","article-title":". The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.","volume":"26","author":"Abedalthagafi","year":"2013","journal-title":"Mod Pathol"},{"key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","article-title":". Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.","volume":"8","author":"Lovejoy","year":"2012","journal-title":"PLoS Genet"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.566910","article-title":". The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3.","volume":"24","author":"Drane","year":"2010","journal-title":"Genes Dev"},{"key":"R30-11-20210131","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cell.2010.01.003","article-title":". Distinct factors control histone variant H3.3 localization at specific genomic regions.","volume":"140","author":"Goldberg","year":"2010","journal-title":"Cell"},{"key":"R31-11-20210131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1101\/gr.101477.109","article-title":". ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells.","volume":"20","author":"Wong","year":"2010","journal-title":"Genome Res"},{"key":"R32-11-20210131","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":". Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.","volume":"27","author":"Liau","year":"2014","journal-title":"Mod Pathol"},{"key":"R33-11-20210131","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2013.167","article-title":"Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma.","volume":"27","author":"Scott","year":"2014","journal-title":"Mod Pathol"},{"key":"R34-11-20210131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":". MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.","volume":"334","author":"Makinen","year":"2011","journal-title":"Science"},{"key":"R35-11-20210131","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":". TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R36-11-20210131","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/modpathol.2013.168","article-title":". TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.","volume":"27","author":"Griewank","year":"2014","journal-title":"Mod Pathol"},{"key":"R37-11-20210131","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.humpath.2013.04.025","article-title":". Clinicopathologic significance of immunostaining of alpha-thalassemiamental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.","volume":"44","author":"Chen","year":"2013","journal-title":"Hum Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000000324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T16:21:26Z","timestamp":1689524486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201502000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000324","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}